Following their early September surprise announcement of a broad alliance, Sumitomo Dainippon Pharma Co. Ltd. (SDP) and Roivant Sciences Inc. have now finalized and fleshed out their $3bn deal under which the Japanese firm will acquire stakes in up to 11 "vant" companies.
Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal
Broad Alliance Involves New Entities
Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.
More from Strategy
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
More from Business
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.